| Identification | Back Directory | [Name]
physalin F | [CAS]
57423-71-9 | [Synonyms]
physalin F
(14S,16β,22R,25S)-5,6β:14,17:14,27-Triepoxy-13,20,22-trihydroxy-1,15-dioxo-16,24-cyclo-13,14-seco-5β-ergost-2-ene-18,26-dioic acid 18,20:26,22-dilactone
14H-17,3-(Epoxymethano)-1,17:2,6-dimethanooxireno[4,4a]naphtho[1,2-f]furo[3,4-b:2,3-c']bisoxocin-4,8,11,21(1H,8aH,10bH)-tetrone, 2,3,6,6a,9,10,10a,15a,16,16a-decahydro-8a-hydroxy-2,6a,10b-trimethyl-, (1S,2S,3S,6R,6aS,8aR,10aS,10bR,14aS,15aR,16aR,17R,18aR)- | [Molecular Formula]
C28H30O10 | [MDL Number]
MFCD30527499 | [MOL File]
57423-71-9.mol | [Molecular Weight]
526.54 |
| Hazard Information | Back Directory | [Uses]
Physalin F is a secosteroid with potent anti-inflammatory and immunomodulatory activities. Physalin F induces apoptosis of PBMC, decreasing the spontaneous proliferation and cytokine production caused by Human T-lymphotropic virus type 1 (HTLV-1) infection[1]. | [Definition]
ChEBI: A physalin with antimalarial and antitumour activities isolated from Physalis angulata. | [References]
[1] Pinto LA, et al. Physalin F, a seco-steroid from Physalis angulata L., has immunosuppressive activity in peripheral blood mononuclear cells from patients with HTLV1-associated myelopathy. Biomed Pharmacother. 2016;79:129-134. DOI:10.1016/j.biopha.2016.01.041 |
|
|